<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818336</url>
  </required_header>
  <id_info>
    <org_study_id>AQ-2010-001</org_study_id>
    <secondary_id>AllerQuest LLC</secondary_id>
    <nct_id>NCT01818336</nct_id>
  </id_info>
  <brief_title>Evaluation of Skin Testing Reagents for Penicillin Allergy</brief_title>
  <official_title>Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral Challenge With Amoxicillin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AllerQuest LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AllerQuest LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A self- or parent-reported history of penicillin allergy excludes approximately 10% of the US
      population from receiving penicillin (Kerr 1994, Kagy, Blaiss 1998, Solensky et al. 2000,
      Neugut et al. 2001). Yet approximately 80% of patients labeled as allergic to the penicillins
      can safely take these antibiotics without fear of a life-threatening reaction (Gadde et al.
      1993, Macy et al. 1997). The outcomes of this erroneous classification of patients include
      unnecessary denial of an effective and well-tolerated class of antibiotics, which are often
      the treatment of choice.

      The primary aim of skin testing with the Penicillin Skin Test Kit is to identify subjects at
      very low risk of developing acute IgE-dependent reactions when given a penicillin or
      cross-reacting drug. The negative predictive value (NPV) of skin testing is assessed by oral
      challenge with a penicillin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label investigation of skin testing with the Penicillin Skin Test
      Kit in subjects at least 18 years of age with a self-reported history of possible
      IgE-dependent penicillin hypersensitivity.

      At screening on Day 1, subjects and their parents/legal guardians (if applicable) will sign
      the informed consent form/ pediatric assent form. Following consent/assent, demographic
      information and medical history will be obtained, including prior and current medication use.
      Subjects will also be asked if they have had a respiratory infection in the past 2 weeks or
      antibiotics within the past 4 weeks. A physical examination will be performed, along with
      measurements of vital signs and, in subjects &gt;5 years of age with active asthma, peak
      expiratory flow rate (PEFR). A urine pregnancy test will be obtained for all female subjects
      of childbearing potential.

      The skin test procedure will first involve puncture testing. Skin test reagents will include
      the Penicillin Skin Test Kit, histamine (positive control), and sodium chloride (negative
      control). Subjects who have negative skin puncture test results to any of the drug antigens
      contained within the Penicillin Skin Test Kit will then undergo intradermal testing in
      duplicate. Subjects who have a positive reaction to one or more puncture or intradermal tests
      contained within the Penicillin Skin Test Kit will be discharged from the study. However,
      subjects with any positive skin test to drug antigens in the Penicillin Skin Test Kit will be
      asked to return for retesting (puncture and intradermal) in 4 weeks.

      Subjects who have negative puncture and intradermal test results will be given the oral
      amoxicillin challenge, which will be comprised of a single, full oral dose of amoxicillin.
      The purpose of the oral amoxicillin challenge is to confirm lack of allergy and confirm the
      NPV (Negative Predictive Value) of skin testing. Subjects will be monitored at the study site
      for 1 hour following oral amoxicillin challenge and then sent home. The study site will
      follow-up by telephone with all subjects (or their parents/legal guardians in the case of
      young children) â‰¥72 hours after administration of the oral amoxicillin challenge.

      Adverse events (AEs) will be recorded from administration of the Penicillin Skin Test
      throughout the 3-day study period as spontaneously reported by subjects or observed by the
      site staff.

      Two normal subjects (i.e., no history of penicillin allergy) will be skin tested at each site
      to provide data on skin test specificity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>72 hours</time_frame>
    <description>The primary endpoint was the negative predictive value (NPV), which was estimated as p = percentage of n history-positive subjects with negative skin tests from the Penicillin Allergy Skin Test Kit (as confirmed with an overall negative result for the skin puncture/intradermal testing) who do not experience an IgE-dependent hypersensitivity reaction within 72 hours of the oral amoxicillin challenge.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">481</enrollment>
  <condition>History of IgE Dependent Reaction to a Penicillin Product</condition>
  <arm_group>
    <arm_group_label>all subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Penicillin skin test kit
Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin skin test kit</intervention_name>
    <description>Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.</description>
    <arm_group_label>all subjects</arm_group_label>
    <other_name>PRE-PEN (benzylpenicilloyl polylysine)</other_name>
    <other_name>MDM (minor determinant mixture of penicillins)</other_name>
    <other_name>benzylpenicillin</other_name>
    <other_name>benzylpenicilloate</other_name>
    <other_name>benzylpenilloate</other_name>
    <other_name>amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have provided written, informed consent prior to performance of any
             procedures.

          2. Subject can be male or female and must be generally healthy and at least 18 years of
             age.

          3. Subject must have a reported history of possible IgE dependent reaction to a
             penicillin or its semi-synthetic derivatives, including one or more of the following:
             anaphylaxis, decreased blood pressure and/or diminished consciousness, upper or lower
             airway obstruction, angioedema, urticaria, and/or generalized pruritic rash.

        Exclusion Criteria:

          1. Subject who has exhibited a systemic allergic reaction to previous skin-test
             administration of PRE-PEN, MDM, or individual penicillin metabolites
             (benzylpenicillin, benzylpenicilloate, or benzylpenilloate).

          2. Subject who is pregnant or lactating.

          3. Subject who has had a respiratory infection within the past 2 weeks or has taken
             antibiotics of any kind during the past 2 weeks (except for topical antibiotics for
             acne).

          4. Subject who has taken an oral H1-antihistamine within 72 hours prior to skin testing.

          5. Subject who has taken hydroxyzine or doxepin within 7 days prior to skin testing.

          6. Subject who has had a penicillin reaction, including semisynthetic penicillins, within
             the last 6 weeks prior to skin testing.

          7. Subject who has received an investigational drug within 30 days prior to skin testing
             or who plans to participate in a study in which an investigational drug will be
             administered within the 30 days following skin testing.

          8. Subjects who have planned hospitalizations or medical or surgical procedures during
             the 72 hours following the oral amoxicillin challenge.

          9. Subjects who plan to take any new prescription or over-the-counter medications or
             herbal supplements during the 72 hours following the oral amoxicillin challenge.

         10. Subject who has had a previous adverse reaction to penicillin or semisynthetic
             derivative and subsequently tolerated a penicillin or semisynthetic derivative without
             an adverse experience.

         11. Subject who, in the investigator's opinion, has any other social or medical condition
             (e.g. fever, rash) that may place the subject at increased risk or may confound the
             interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Franklin Adkinson, Jr., MD</last_name>
    <role>Study Director</role>
    <affiliation>AllerQuest LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Allergy &amp; Asthma Center</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairfield County Allergy, Asthma &amp; Immunology Assoc., Inc.</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ct. Asthma &amp; Allergy Center LLC</name>
      <address>
        <city>West Hartford</city>
        <state>Connecticut</state>
        <zip>06119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windom Allergy</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Allergy and Asthma Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Allergy &amp; Asthma Clinic PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corvallis Clinic</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Care</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Asthma &amp; Allergy Center</name>
      <address>
        <city>Redmond</city>
        <state>Washington</state>
        <zip>98052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>November 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2017</results_first_posted>
  <last_update_submitted>November 6, 2016</last_update_submitted>
  <last_update_submitted_qc>November 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>penicillin allergy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Penicillins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a prospective, open-label investigation of skin testing with the Penicillin Skin Test Kit conducted at 13 asthma and allergy centers in the United States.</recruitment_details>
      <pre_assignment_details>455 History pos subj enrolled + 2 control subj @ 13 centers. All 481 subj were skin tested(ST) and included in safety population. 64 subj (all history pos) had pos or discordant skin tests and were excluded from ITT population of 391(455 - 64). The subset of 59 ST pos subjects were invited back at 4 weeks for repeat ST; 47 ST pos subj returned</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intent-to-Treat Population</title>
          <description>All subjects who had valid skin testing performed (i.e., administered all components of the Penicillin Skin Test Kit and the histamine and control results were valid) and who received the oral amoxicillin challenge.</description>
        </group>
        <group group_id="P2">
          <title>Subjects in Retest Population</title>
          <description>All subjects who initially tested positive to any of the initial skin tests with penicillin reagents and subsequently returned after 4 weeks for retesting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declined retest visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total subjects enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Safety Population</title>
          <description>All subjects who had skin testing performed (i.e., administered any component of the Penicillin Skin Test Kit).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="481"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Safety population is equal to all enrolled subjects. ITT, Per-protocol, and Re-skin tested subpopulations have been defined elsewhere.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Safety Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="16.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intent-to-Treat Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Per-Protocol Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="373"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="16.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retest Population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="440"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Penicillin allergy history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous penicillin testing history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Predictive Value</title>
        <description>The primary endpoint was the negative predictive value (NPV), which was estimated as p = percentage of n history-positive subjects with negative skin tests from the Penicillin Allergy Skin Test Kit (as confirmed with an overall negative result for the skin puncture/intradermal testing) who do not experience an IgE-dependent hypersensitivity reaction within 72 hours of the oral amoxicillin challenge.</description>
        <time_frame>72 hours</time_frame>
        <population>The Intent-to-Treat Population; all subjects with valid skin testing performed (ie, administered all components of the penicillin skin test kit and the histamine/control results were valid), who had negative intradermal skin tests with all 3 Kit reagents, and who received the oral amoxicillin challenge</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-to-Treat Population</title>
            <description>All subjects who had valid skin testing performed (i.e., administered all components of the Penicillin Skin Test Kit and the histamine control results are valid) and who receive the oral amoxicillin challenge.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value</title>
          <description>The primary endpoint was the negative predictive value (NPV), which was estimated as p = percentage of n history-positive subjects with negative skin tests from the Penicillin Allergy Skin Test Kit (as confirmed with an overall negative result for the skin puncture/intradermal testing) who do not experience an IgE-dependent hypersensitivity reaction within 72 hours of the oral amoxicillin challenge.</description>
          <population>The Intent-to-Treat Population; all subjects with valid skin testing performed (ie, administered all components of the penicillin skin test kit and the histamine/control results were valid), who had negative intradermal skin tests with all 3 Kit reagents, and who received the oral amoxicillin challenge</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="96.6" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded immediately following administration of the Penicillin Skin Test and throughout the 3-day study period as spontaneously reported by subjects, reported during the phone interview â‰¥72-hours post-oral challenge, or observed by the site staff.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety Population-All Study-Emergent Adverse Events</title>
          <description>Intervention: Penicillin skin test kit
The skin test procedure first involved puncture testing. Subjects who had negative skin puncture test results to any of the drug antigens contained within the Penicillin Skin Test Kit then underwent intradermal testing in duplicate. Subjects who had any positive skin test to drug antigens in the Penicillin Skin Test Kit were asked to return in 4 weeks to confirm the positive test(s). Subjects who had negative puncture and intradermal test results were given the oral amoxicillin challenge, which was comprised of a single, age-dependent, full oral dose of amoxicillin. The purpose of the oral amoxicillin challenge was to confirm absence of allergy and confirm the NPV of skin testing. Subjects were monitored at the study site for 1 hour following oral amoxicillin challenge and then sent home. The study site followed up by telephone with all subjects â‰¥72 hours after administration of the oral amoxicillin challenge.</description>
        </group>
        <group group_id="E2">
          <title>Subjects With AE Related to Skin Testing</title>
          <description>Intervention: Penicillin skin test kit
The skin test procedure first involved puncture testing. Subjects who had negative skin puncture test results to any of the drug antigens contained within the Penicillin Skin Test Kit then underwent intradermal testing in duplicate. Subjects who had any positive skin test to drug antigens in the Penicillin Skin Test Kit were asked to return in 4 weeks to confirm the positive test(s).</description>
        </group>
        <group group_id="E3">
          <title>Subjects With AE Related to Oral Amox Challenge</title>
          <description>Intervention: Penicillin skin test kit
The skin test procedure first involved puncture testing. Subjects who had negative skin puncture test results to any of the drug antigens contained within the Penicillin Skin Test Kit then underwent intradermal testing in duplicate. Subjects who had any positive skin test to drug antigens in the Penicillin Skin Test Kit were asked to return in 4 weeks to confirm the positive test(s). Subjects who had negative puncture and intradermal test results were given the oral amoxicillin challenge, which was comprised of a single, age-dependent, full oral dose of amoxicillin. The purpose of the oral amoxicillin challenge was to confirm absence of allergy and confirm the NPV of skin testing. Subjects were monitored at the study site for 1 hour following oral amoxicillin challenge and then sent home. The study site followed up by telephone with all subjects â‰¥72 hours after administration of the oral amoxicillin challenge.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.2</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Angiodema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Post-procedural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="481"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="481"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Franklin Adkinson Jr., MD-Vice President, Chief Medical Officer</name_or_title>
      <organization>AllerQuest</organization>
      <phone>410-550-2051</phone>
      <email>fadkinson@allerquest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

